Skip to main content
. Author manuscript; available in PMC: 2013 Aug 21.
Published in final edited form as: JAMA. 2013 May 1;309(17):1803–1809. doi: 10.1001/jama.2013.3710

Figure 1.

Figure 1

Reasons for Exclusion of Clinic Patients From the Study Cohort

aThe patients who initiated a protease inhibitor–based treatment were enrolled in a clinical trial. A few patients began taking 2 nucleoside reverse transcriptase inhibitors before highly active antiretroviral therapy was available.

bIncluded in death and loss to follow-up counted as virological failure subanalysis.